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The calcitonin gene-related peptide (CGRP) receptor is a het-
erodimer of a family B G-protein-coupled receptor, calcitonin
receptor-like receptor (CLR), and the accessory protein receptor
activity modifying protein 1. It couples to Gs, but it is not known
which intracellular loops mediate this. We have identified the
boundaries of this loop based on the relative position and length of
the juxtamembrane transmembrane regions 3 and 4. The loop has
been analyzed by systematic mutagenesis of all residues to alanine,
measuring cAMP accumulation, CGRP affinity, and receptor
expression. Unlike rhodopsin, ICL2 of the CGRP receptor plays a
part in the conformational switch after agonist interaction. His-216
and Lys-227 were essential for a functional CGRP-induced cAMP
response. The effect of (H216A)CLR is due to a disruption to the cell
surface transport or surface stability of themutant receptor. In con-
trast, (K227A)CLR had wild-type expression and agonist affinity,
suggesting a direct disruption to the downstream signal transduc-
tion mechanism of the CGRP receptor. Modeling suggests that the
loop undergoes a significant shift in position during receptor acti-
vation, exposing a potential G-protein binding pocket. Lys-227
changes position to point into the pocket, potentially allowing it to
interact with boundG-proteins. His-216 occupies a position similar
to that of Tyr-136 in bovine rhodopsin, part of the DRYmotif of the
latter receptor. This is the first comprehensive analysis of an entire
intracellular loopwithin the calcitonin family of G-protein-coupled
receptor. These data help to define the structural and functional
characteristics of the CGRP-receptor and of family B G-protein-
coupled receptors in general.
G-Protein coupled receptors (GPCRs)2 comprise a large superfamily
of membrane-spanning proteins encoded by 2–3% of the human
genome. These receptors respond to an incredibly diverse array of stim-
uli fromodorants, amines, peptides, and light through a series of broadly
similar activationmechanisms and accessory proteins. The pharmaceu-
tical implications of understanding these proteins cannot be underesti-
mated, and the crystal structure of rhodopsin has presented many new
avenues of study for this family (1).
Several structural and functional motifs are well characterized within
the intracellular domains of the largest known family (A) of GPCRs.
These include the conserved (D/E)R(Y/H) motif on the boundary
between transmembrane helix 3 and the second intracellular loop
(ICL2) and which is well documented to have a significant role in the
activation mechanism (2) and the NPXXY motif of TM7, which can
have diverse roles in the constitutive phosphorylation, internalization,
and signaling of many family A GPCRs (3, 4). In addition, residues
within ICL2 juxtaposed to transmembrane helix 3 have been shown to
be involved in receptor stability (5).
In contrast, much less is known about the important amino acids of
family B receptors, which include the calcitonin family of receptors and
which tend to bind larger peptide agonists. There are no obvious com-
mon motifs between family A and family B receptors; nevertheless, a
shared mechanism involving a ligand-induced conformational distor-
tion between the distal regions of TMs 3 and 6 has been proposed for the
parathyroid hormone receptor (6) and the CGRP/adrenomedullin
receptors (7). There are contrary reports arguing for the involvement of
the second intracellular loop in receptor expression and activation
within the family B GPCRs. A recent study on the VPAC1 receptor
found that all residues of ICL2 could be mutated without alteration of
receptor expression or adenylyl cyclase response to vasoactive intestinal
peptide (8). Conversely, a lysine residue in ICL2 of the parathyroid hor-
mone (PTH) receptor was shown to be critical in activating the phos-
pholipase C pathway while having no effect on the adenylyl cyclase
response (9).
The family B receptor CLR is unusual among GPCRs in that it
requires the co-expression of one of a family of accessory proteins called
RAMPs (receptor activity modifying proteins) for cell trafficking and
ligand interaction (10). A functional CGRP receptor is formed by a
CLR/RAMP1 heterodimer (11). In addition, an agonist-mediated sig-
naling response requires the co-localization of a third membrane-asso-
ciated accessory protein called the receptor component protein (12).
Receptor component protein is thought to form an ionic interaction
with the membrane adjacent to CLR (13). There are no studies explor-
ing the role of intracellular regions of CLR involved in CGRP binding,
cAMP signaling, or protein expression; indeed there are very fewmuta-
tional analyses of the second intracellular loop for any family B GPCRs.
This report describes the systematic substitution of all residues of
ICL2 of human CLR.Mutations were constructed either individually or
in pairs replacing the side chains with a single methyl group (alanine).
The naturally occurring alanine residues at position 221 and 224 were
replaced with glycine. Thesemutants were transfected intomammalian
cells in combination with a RAMP1 construct and analyzed using a
tritiated cAMP radio receptor assay. The assay compared the CGRP-
stimulated cAMP accumulation of mutant with wild-type CLR.
Mutants with impaired function were further characterized for cellular
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expression, ligand affinity, and surface localization.We identify His-216
and Lys-227 as key residues for normal receptor function and utilize
molecular modeling to reveal the likely spatial positioning of the second
intracellular loop in the predicted active and inactive states of the recep-
tor. Our findings are discussed in the context of previously proposed
motifs within this region in other family B receptors.
EXPERIMENTAL PROCEDURES
Materials—Human CGRP was from Calbiochem. Peptides were
dissolved in distilled water and stored as aliquots at20 °C in non-stick
microcentrifuge tubes (Thermo Life Sciences, Basingstoke, UK). Unless
otherwise specified, chemicals were from Sigma or Fisher. Cell culture
reagents were from Invitrogen or Sigma. [125I]Iodohistidyl8-human
CGRP (2000 Ci/mmol) was from Amersham Biosciences.
ExpressionConstructs andMutagenesis—HumanCLRwith anN-ter-
minal hemagglutinin (HA) epitope tag (YPYDVPDYA) (14) was pro-
vided by Dr. S. M. Foord (GlaxoSmithKline) and was subcloned into
pcDNA3() (Invitrogen) before mutagenesis. Introduction of the
epitope did not affect the pharmacology of the receptor (14).
Mutagenesis was carried out using the QuikChange site-directed
mutagensis kit (Stratagene, Cambridge, UK), following themanufactur-
er’s instructions. Forward and reverse oligonucleotide primers were
designed with single base changes to incorporate amino acid point
mutations alanine (or glycine) in the final CL protein and to engineer
restriction sites to aid screening of mutants. The primers were synthe-
sized by Invitrogen. The numbering of the residues accommodates a
22-amino acid signal protein before the start of the mature transcript
(15).
Plasmid DNA was extracted from the cultures using a Wizard-Prep
DNA extraction kit according to the manufacturer’s instructions (Pro-
mega, Southampton, UK). The plasmid DNA was eluted in 100 l of
sterile distilled water and stored at20 °C. Sequences were confirmed
by sequencing (Functional Genomics, Birmingham, UK).
Cell Culture and Transfection—Cos-7 cells were cultured in Dulbec-
co’s modified Eagle’s medium supplemented with 10% (v/v) fetal bovine
serum and 5% (v/v) penicillin/streptomycin in a humidified 95% air, 5%
CO2 atmosphere. For transfection, the cells were plated onto either 12-
and 48-well plates or 100-mm dishes. Cells were transfected using a
mixture (per 1g ofDNA) of 6l of 10mMpolyethyleneimine and 45l
of 5% glucose solution incubated for 30 min at room temperature and
added to an appropriate final volume of full media. 12- and 48-well
plates were treated with 1 g of DNA/well, and 100-mm dishes were
treated with 10 g of DNA/dish. Characterization of expressed recep-
tors was performed 48–72 h after transfection.
Membrane Preparation—The cells from each 100-mm plate were
washed briefly with 1 ml of cold phosphate-buffered saline and scraped
into a small volume of buffer (20 mM HEPES, 2 mM MgCl2, 1% (w/v)
bovine serum albumin (BSA), pH 7.5). The cells were homogenized
using an Ultra Turrax homogenizer (full speed for 20 s). The cells were
then centrifuged at 20,000 g for 30 min at 4 °C. The supernatant was
removed, and the pellets were resuspended in 14ml of buffer (as before)
and used immediately for binding studies or stored at70 °C.
Radioligand Binding—Membranes were homogenized briefly before
use, and 500 l were incubated with 100 pM [125I]iodohistidyl8-human
CGRP and appropriate dilutions of humanCGRP for 60min at room
temperature. Nonspecific binding was measured in the presence of 1
MCGRP. The samples were then centrifuged at 12,000 g in a bench-
top microcentrifuge for 5 min at room temperature. The pellets were
washed twice with water, and the radioactivity was counted in a 
counter.
Assay of cAMP Production—Growth medium was removed from the
cells and replaced with Dulbecco’s modified Eagle’s medium containing
500 M isobutylmethylxanthine for 30 min. CGRP in the range 10 pM
to 1 Mwas added for a further 15 min. Ice-cold ethanol (95–100% v/v)
was used to extract cAMP, which was subsequently measured by radio-
receptor assay as previously described (16)
Analysis of Cell-surface Expression of Mutants by Enzyme-linked
Immunosorbant Assay (ELISA)—Cells in 12-well plates were transiently
transfected with wild type (WT) or mutant HA epitope-tagged human
CL and RAMP 1. The transfected cells were treated with 3.7% formal-
dehyde for 15 min after aspiration of growth medium. The cells were
then washed 3 times with 0.5 ml of Tris-buffered saline (TBS). Nonspe-
cific binding of the antibody was blocked with 1% BSA in TBS for 45
min. The cells were treated with 250 l of primary antibody (mouse,
anti-HA antibody 12CA5 (Sigma) diluted 1:1000 in TBS with 1% BSA)
for 1 h, and the cells were washed again 3 times with 0.5 ml of TBS. A
further block step was performed for 15 min before the cells were incu-
bated with 250 l of secondary antibody (anti-mouse, horseradish per-
oxidase-conjugated (Sigma) diluted 1:1000 in TBS) for 1 h. The cells
were washed a further three times before development with O-phen-
ylenediamine tablets (Bio-Rad) according to the manufacturer’s
instructions. Reactions were terminated with 100l/well of 1 MH2SO4.
The absorbancemeasured by the ELISA showed a linear dependence on
the DNA concentration used in the transfection.
Immunohistocytochemistry—Cos-7 cells were seeded in 6-well plates
containing nitric acid-washed glass coverslips (12 mm) and transfected
using polyethyleneimine as described above. Cells were fixed and
washed with phosphate-buffered saline (PBS) as described previously
for the ELISA. Cells were blocked with 1% BSA in PBS for 45 min
followed by incubation with an anti-HA primary antibody (diluted to
1:3000 in 3% (w/v) for 60 min. Cells were washed 3 times with PBS
before reblocking with 1% BSA in PBS for 15 min at room temperature.
Cells were labeled with a staining mixture including goat anti-mouse
IgG conjugated to fluorescein isothiocyanate (Sigma) (diluted to 1:500
in 10% (v/v) goat serum in PBS), Alexa 546 phalloidin (Molecular
Probes, Leiden, The Netherlands), and Hoescht 33342 (Sigma) for 60
min at room temperature in the dark. After a further three washes,
coverslips were mounted on glass slides before confocal microscopy.
Confocal Microscopy—Confocal microscopy was performed using a
Nikon Optiphat II laser scanning microscope at 60 magnification
under immersion oil. The HA-tagged receptors were visualized by
exciting the secondary antibody, actin filaments were visualized by
exciting the Alexa 546 phalloidin, and nuclei were visualized by exciting
the Hoescht 33342. The appropriate wavelength was used according to
manufacturer’s instructions in each case. Images were captured at 10
random sites for each slide from three separate experiments.
TM Prediction—Individual TM helix prediction of 58 diverse Family
B GPCR sequences was performed using the web-based versions of
TMHMM2 (17) and HMMTOP2 (18). A consensus prediction for the
boundaries of TMIII and TMIVwas generated by visual inspection, and
from this initial survey, a ClustalW (19) profile alignment (using the
Blosum matrix) was created against 58 peptide hormone family A
GPCRs. The resulting alignment was used to generate an initial homol-
ogy based model using the high resolution x-ray crystal structure of
bovine rhodopsin as a template. Further refinement of the homology
model was achieved through molecular dynamics (MD) simulations of
the receptor embedded in a dipalmitoylphosphatidylcholine bilayer. A
series (n 5) of 5-ns MD simulations were carried out using the GRO-
MOS96 force field parameter set, with minor modifications, as imple-
mented in GROMACS (20). The resulting trajectories were concate-
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nated and used to produce the final refinedmodel of theCLR.The active
state of the CLR was achieved through the use of a modified rhodopsin
template, which was consistent with experimentally derived distance
restraints obtained from the literature (21–25). Homology models of
the active CLR were refined through the use of MD simulations as
described above.
Prediction of the ICL2 of Rhodopsin and the CLR—RAPPER was used
to predict from first principles (ab initio) the conformations of ICL2
from rhodopsin and the CLR. Briefly, 1000 loop backbone conforma-
tions were generated using RAPPER assuming idealized stereochemis-
try for all heavy atoms (N, C, C, O). The side-chain orientations for the
predicted backbone conformations were modeled using SCWRL (26)
within the environment of the remaining, non-modeled protein. Gen-
erated fragments were initially scored using an all-atom statistical
potential (scop-e4-allatoms-x-ray-scores scoring set) as described by
Samudrala and Moult (27). The ensemble of loop conformations was
filtered on the basis of a RADPF score such that nomore than the top 50
models were retained for energy minimization. Minimization was per-
formed using a l-BFGS minimization method which utilized the
AMBER all-atom force-field (parm99) together with the Still GB/SA
solvation model, as implemented in the TINKER (28). Minimization
was performed until either convergence or a 0.1-kcalmol1 cutoff point
was reached. Only atoms belonging to either the loop region or the
N/C-terminal anchor residues were allowed to move during minimiza-
tion. Minimized fragments were subsequently ranked according to the
conformational free energy of the loop.
Data Analysis—Curve fitting was done with PRISM Graphpad 4
(Graphpad Software Inc., San Diego, CA). For cAMP studies, the data
from each concentration-response curve were fitted to a sigmoidal con-
centration-response curve to obtain the maximum response and
logEC50 (pEC50). For radioligand binding experiments curves were
fitted to obtain maximum and minimum amounts of binding and
logIC50 (pIC50). Because the radioligand was present at concentra-
tions well below itsKd, the IC50 values were effectively identical to theKi
values. To estimate Bmax values with 125I-labeled CGRP, the data were
fitted to a sigmoidal curve, calculating the amount bound from the
specific activity of the radioligand (this was progressively reduced by
dilution with unlabeled CGRP). pEC50, pIC50, and Bmax values were
compared by paired Student’s t test. Comparisons were only made
between wild-type (WT) and mutant data from concomitantly trans-
fected cells. A control WT experiment was always performed alongside
a mutant experiment.
RESULTS
Identification of the Boundaries of ICL2—According to the Swiss-
Prot data base entry Q16602 (www.ExPasy.org), ICL2 of the CLRwould
be predicted to encompass residues from (and including) Leu-215 to
Met-230. An alignment of this region of 57 family B GPCRs in Table 1
shows the most conserved amino acids. The TM/loop boundaries were
more precisely defined by using a consensus of previously validated TM
prediction methods and remote sequence alignment to a known struc-
ture. Visual inspection of the TM prediction results revealed that,
although the boundaries for TM4 were well defined, those for TM3
exhibited variability. Essentially, the predicted boundaries for TM3
were clustered into two populations. The first population, which
included the majority of sequences studied (40 of 58), exhibited a TM3
boundary at the equivalent position to residues 214 and 243 (including
the signal peptide) of the CLR. Significantly, this would position the
conserved cysteine residue located at the extracellular end of TM3 in
the same positions as that observed in family A receptors. The bound-
aries for TM3 of the second, smaller population was between the equiv-
alent residues to 227 and 247 (CLR). We have, therefore, used the
boundaries exhibited by the first, larger population for subsequent loop
modeling studies. As previously mentioned, the predicted boundaries
for TM4 were well defined and included residues 250–270 (CLR). Fur-
thermore, sequence alignment of the predicted TM4 segment against
the residues corresponding to the high resolution x-ray crystal structure
of rhodopsin positioned a conserved tryptophan residue found in both
family A and B GPCRs in the same position.
Effect of ICL2 Substitution Mutants on cAMP Accumulation—To
identify the contribution toCGRP-stimulated signaling provided by res-
idues within this ICL2 and adjoining segments, residues between Tyr-
214 and Tyr-233 inclusive (see Fig. 1) were mutated to alanine either
individually or in pairs to generate the constructs (Y214A/L215A)CLR,
(H216A)CLR, (T217A)CLR, (L218A/I219A)CLR, (V220A/V221A)-
CLR, (A222G)CLR, (V223A/F224A)CLR, (A225G)CLR, (E226A)CLR,
(K227A)CLR, (Q228A/H229A)CLR, (L230A/M231A)CLR, (W232A)-
CLR, and (Y233A)CLR. Each mutant receptor construct was co-
expressed with a RAMP1 vector in Cos-7 cells, and the CGRP-stimu-
lated cAMP accumulation was compared with wild-type CLR. In each
FIGURE1.Aminoacid sequenceof ICL2 fromhumanCL showing thepositionsof the
mutated residues. Residues in black showed reductions in the CGRP-stimulated adeny-
late cyclase activation in this study. Residue numbering is from the start of the predicted
mature transcript of CLR (15).
TABLE 1
Conservation of residues within ICL2 of CLR
ICL2 boundaries are assumed from the model presented in this study. The table compares CLR with 57 diverse GPCR examples from family B taken from www.expasy.ch.
CLR % Identity CLR % Identity CLR % Identity
Tyr-214 100 Val-221 15 Gln-228 18
Leu-215 100 Ala-222 27 His-229 19
His-216 56 Val-223 21 Leu-230 34
Thr-217 47 Phe-224 42 Met-231 26
Leu-218 71 Ala-225 29 Trp-232 19
Ile-219 48 Glu-226 50 Tyr-233 45
Val-220 36 Lys-227 28
The Second Intracellular Loop of CLR
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case during this study, the natural-CGRP agonist was used to generate
dose response curves.
As shown in Fig. 2a and Table 2, the pEC50 for cAMP production in
response to CGRP was not significantly different for the seven alanine
substitution mutants (Y214A/L215A)CLR, (T217A)CLR, (L218A/
I219A)CLR, (V220A/V221A)CLR, (Q228A/H229A)CLR, (L230A/
M231A)CLR, and (Y233A)CLR or the two glycine substitutionmutants
(A222G)CLR and (A225G)CLR when compared with WT CLR
co-transfected with RAMP1. Additionally, none of the point mutations
in this study had basal levels of stimulation in excess of that seen for the
wild-type receptor (data not shown). This suggests none of these sub-
stitution mutations forms a constitutively active receptor.
In contrast to the mutants described above, two constructs including
a double alanine substitution of the valine and phenylalanine residues at
positions 223 and 224 (V223A/F224A)CLR as well as a single mutation
of tryptophan to alanine at position 232 (W232A)CLR, both resulted in
a small loss in the ability of CLR to elevate cAMP in response to CGRP
(Table 2 and Fig. 2, b and c). The disruption in signaling resulted in a
significant reduction in the pEC50 value of 4- and 2.6-fold for mutants
(V223A/F224A)CLR and (W232A)CLR, respectively. However, when
the His-216 or Lys-227 were mutated to alanine, the perturbation of
cAMP was larger, with greater than an order of magnitude reduction in
EC50 (Table 2 and Fig. 2, d and e). This reduction corresponds to an 11-
and 11.5-fold decrease for (H216A)CLR and (K227A)CLR, respectively.
It is not without precedent that the effects of removing a basic residue
such as Lys-227 are due to the destabilization of a salt bridge formed by
an adjacent cationic side chain left without an ionic partner (in this case
Glu-226), disrupting stability. To investigate this possibility, we con-
structed and analyzed a double mutant, (E226A/K227A)CLR. The sig-
naling profile of this mutant was not significantly different to the effects
seen by the (K227A)CLR mutant alone (pEC50 values for wild-type and
(E226A/K227A)CLRwere 8.79 0.08 and 8.28 0.09, respectively, n
3). These data suggest a direct role for the basic lysine side chain in the
activation mechanism of the receptor.
ELISA Analysis of Cell-surface Expression—The mutants with dis-
rupted cAMP signaling were subsequently analyzed for their compara-
tive ability to traffic to the cell surface using a whole-cell enzyme-linked
immunosorbent assay to detect the surface expression of the engineered
FIGURE 2. CGRP-stimulated cAMP response of the ICL2 mutants. Cos-7 cells were
transfected with WT/RAMP1 or mutant/RAMP1 and assayed for CGRP-stimulated cAMP
production.Open circles, WT type receptors. Mutant receptors are as indicated. Data are
representative of three to four similar experiments. Points are the mean S.E. of tripli-
cate points. a, mutations with wild-type cAMP signaling; b, (V223A/F224A)CLR; c,
(W232A)CLR; d, (H216A)CLR; e, (K227A)CLR.
TABLE 2
Functional parameters of WT/RAMP1 andmutant receptors
Values are the mean S.E; the number of determinations is shown in parentheses.
The maximum responses (Emax) were not significantly different from the concom-
itantly expressedWT receptor for all of the mutants in this study (data not shown).
Mutant WT pEC50 pEC50
(Y214A/L215A)CLR 9.02 0.21 (3) 8.91 0.36 (3)
(H216A)CLR 9.41 0.13 (3) 8.37 0.37(3)a
(T217A)CLR 9.36 0.21 (3) 9.33 0.35 (3)
(L218A/I219A)CLR 9.66 1.01 (3) 9.37 1.04 (3)
(V220/V221A)CLR 9.75 0.36 (3) 9.64 0.11 (3)
(A222G)CLR 9.54 0.12 (3) 9.54 0.34 (3)
(V223A/F224A)CLR 9.62 0.05 (3) 9.02 0.13(3)b
(A225G)CLR 9.43 0.21 (3) 9.34 0.19 (3)
(E226A)CLR 10.07 0.09 (3) 9.87 0.20 (3)
(K227A)CLR 9.97 0.37 (3) 8.91 0.23(3)a
(Q228A/H229A)CLR 9.60 0.75 (3) 9.55 0.52 (3)
(L230A/M231A)CLR 9.44 0.21 (3) 9.65 0.39 (3)
(W232A)CLR 9.27 0.10 (3) 8.85 0.32(3)b
(Y233A)CLR 8.84 0.06 (3) 8.50 0.10 (3)
a Significantly different fromWT, p 0.01, as assessed by paired Student’s t test.
b Significantly different fromWT, p 0.05, as assessed by paired Student’s t-test.
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HA-tag epitope. The ELISA data are shown graphically in Fig. 3a, and
maximum absorbance values (ABmax) are summarized with their S.E. in
Table 3. The alanine substitutions to the hydrophobic residues Val-223/
Phe-224 and Trp-232 approximately halved cell-surface expression to
54.2 6.2 and 61.8 3.8% of wild type, respectively. (H216A)CLR was
barely detected at the cell surface, with an expression level just 10.2 
3.2% of wild type. (K227A)CLR shows cell-surface expression levels
comparable with wild type (90.9 10.8%).
To validate that the ELISA analysis presents a valuablemeasure of cell
surface expression, we investigated the cell surface localization of HA-
tagged CLR using immunofluorescence confocal microscopy (Fig. 3b).
As expected, no signal was visible in cells transfected with untagged
RAMP1 alone (Fig. 3b, i). When HA-CLR was co-expressed with
RAMP1, fluorescence was seen both inside the cell and on the plasma
membrane (Fig. 3b, ii). In cells transfected with HA-CLR alone, little
fluorescence was seen on the plasma membrane, although there was
intense intracellular staining (Fig. 3b, iii). Although the microscopy
experiments are a qualitative measure and cannot be a sound basis for
estimates of total cellular expression, they confirmed the cell surface
expression of these receptors, thus demonstrating the ELISA represents
genuine surface expression.
Radioligand Analysis of Total Cell Receptor Expression (Bmax)—The
total cellular expression of transfected receptors was compared with
wild type using radioligand binding analyses. Total expression (Bmax)
values were estimated from 125I-labeled CGRP radioligand binding, cal-
culating the amount bound by diluting the specific activity of the tracer
radioligand with unlabeled CGRP. There was no significant difference
betweenBmax values for any of themutants and control (Table 3), show-
ing that the reduced surface expression seen for (V223A/F224A)CLR,
TABLE 3
Expression and CGRP affinty of mutant receptors
Values are the mean S.E.; the number of determinations is shown in parentheses.
Bmax and Kd values determined from [125I]-CGRP radioligand binding. ABmax; rela-
tive cell surface expression of receptors as measured by detection of HA tags in an
ELISA. Data are normalized to WT as 100%.
Mutant Bmax ABmax Kd
pmol/mg nM
WT 1.60 0.48 (12) 100 (3) 8.71 0.07 (9)
H216A 1.45 0.50 (3) 10.2 3.2 (3)a 8.47 0.09 (3)
V223A/F224A 2.91 0.96 (3) 54.2 6.2 (3)a 8.60 0.19 (3)
K227A 1.62 0.16 (3) 90.9 10.8 (3) 9.16 0.43 (3)
W232A 1.02 0.36 (3) 61.8 3.8 (3)a 8.62 0.16 (3)
a Significantly different fromWT; p 0.05 compared toWTusing one-way analysis
of variance followed by Dunnett’s test.
FIGURE 3. a, ELISA for H216A, V223A/F224A,
K227A, andW232A. Surface expression of the four
mutants with effects on adenylate cyclase activa-
tion is shown. **, significantly different from con-
trol; p 0.01, 1-way analysis of variance followed
by Dunnett’s test. b, confocal microscopy. Cos-7
cells were transiently transfected with HA-tagged
CLR and RAMP1. Cells were fixed, and immunohis-
tocytochemistry was processed as shown under
“Experimental Procedures.” Images are represent-
ative from three separate experiments. i, cell trans-
fected with RAMP1 alone; ii, cell transfected with
HA-CL and RAMP1; iii, cell transfected with HA-CL
alone.
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[W232]CLR, and (H216A)CLR was reflective of a reduced localization
or surface stability and not reduced protein expression or grossmisfold-
ing of the receptor.
CGRP Affinity-measured Using Radioligand Displacement Studies—
In contrast to the reduced signaling efficacy of the above four mutants,
CGRP-affinity measured using 125I-labeled CGRP radioligand bind-
ing experiments was unaffected. Binding curves are shown in Fig. 4
with pKd values presented in Table 3. This supports the suggestion
that the effects seen by (H216A)CLR, (V223A/F224A)CLR, and
[W232]CLR are not indirect effects on agonist binding. Interestingly,
the wild-type affinity shown by (K227A)CLR suggests an effect on
the activation mechanism of the CGRP receptor that is structurally
downstream of conformational switch from ground state (R) to the
high affinity activated state (R*). The affinity of CGRP to the ground
state of CLR/RAMP1 heterodimer has previously been shown to be
reduced (7).
Loop Modeling—To further understand the effects of (K227A)CLR
and (H216A)CLR, we set about to construct models of ICL2 in the
probable inactive and active conformations of CLR. To assess the effec-
tiveness of a loop modeling protocol, it must first be able to predict the
conformation of loops from a protein whose structure has been solved
to high resolution. Rhodopsin is the only GPCR whose structure is
known in atomic detail, and as such, we have used the protocol of de
Bakker et al. (29) to predict the conformation of ICL2.
The ICL2 of bovine rhodopsin is defined by the sequence 140CKPM-
SNFRFG149, where C140 and G149 represent the intracellular ends of
TM3 and TM4, respectively. Fig. 5, a and b, show the backbone confor-
mation of the native structure, and superimposed on this is the highest-
scored predicted conformation of ICL2 that was selected from an initial
ensemble of 1000 random conformations. It is clear that the use of the
AMBER/GBSA energy function resulted with the selection of a confor-
mation with a fold that was very close to the native loop. Structural
deviation between the native and predicted conformation of ICL2 was
measured, which resulted with a heavy atom root mean-squared devia-
tion of less than 1.0 Å.
The Predicted Structure of ICL2 of CLR—It is reasonable to assume
that the conformation of the framework on which the loops are pre-
dicted would have an impact on the final loop orientation. With this in
mind we have performed the same method as discussed above for
bovine rhodopsin, on ICL2 from the CL receptor under two different
starting conditions to explore the effects of conformational change on
the orientation of the loop. The conditions for the loop predictionswere
1) homology modeling and MD refinement based on the ground state
x-ray crystal structure coordinates of bovine rhodopsin and 2) molecu-
FIGURE 4. Displacement of 125I-labeled CGRP by unlabeled CGRP at the four func-
tionally important mutants compared with WT. Cos-7 cells were transfected with
WT/RAMP1 or mutant/RAMP1, and membranes were assayed for 125I-labeled CGRP
binding. Open circles, WT type receptors. Mutant receptors are as indicated. Data are
representative of three to four similar experiments. Points are the mean S.E. of tripli-
cate points.
FIGURE 5. Loop modeling of ICL2 from bovine
rhodopsin and CLR. a and b, the backbone con-
formation of the highest scored loop prediction of
rhodopsin ICL2 from the side and top, respectively
(conformation of the x-ray crystal structure
orange, best scored prediction blue). Whereas the
complete TM bundle was used for the prediction
of ICL2 only, TM3 and TM4 are shown for clarity. A
backbone atom rootmean-squared deviationwas
calculated between the native and predicted loop
conformations and resulted in less than a 1-Å dif-
ference. c, ICL2 of the CLR in the inactive (red) and
proposed active states (green) showing how lysine
227 changes orientation. d, ICL2 of the CLR in the
inactive (red) and proposed active states showing
how the side chains of valine 223 and phenylala-
nine 224maintain their orientationwith respect to
each other despite their translocation. e, compari-
son of the position of histidine 216 in CLR with
tyrosine 136 of bovine rhodopsin.
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lar modeling, which utilized a refined TM helical bundle based experi-
mentally derived distance constraints, which are consistent with an
active conformation of bovine rhodopsin.
Comparison of the loop predictions for each of the starting con-
ditions revealed distinct loop conformations for the inactive and a
proposed active state of the receptor (Fig. 5c). It is clear that in the
predicted inactive conformation, ICL2, acts to occlude the intracel-
lular portion of the receptor. In contrast, the proposed active state
revealed a conformational change that would allow access of G-pro-
teins with the intracellular portion of the receptor. This is in contrast
to the x-ray crystal structure of bovine rhodopsin where ICL2 does
not act as a steric constraint in the inactive state of the receptor.
However, several molecular dynamic studies (30) have demonstrated
an increased root mean-squared fluctuation of the intracellular loops
compared with the remainder of the protein, which is consistent
with the B-factors found in the structural Protein Data Bank file.
This suggests that ICL2 is dynamic and may adopt other conforma-
tions that are not observed in the rhodopsin x-ray crystal structures.
In the model, the residues that alter cAMP production all undergo
distinct conformational changes. The side chain of Lys-227 moves so
that it is orientated toward the putative G-protein binding pocket in
the active state of the receptor (Fig. 5c). Val-233 and Phe-234
undergo significant translations, but the relative orientations of their
side chains relative to each in the active and inactive other remain
constant; no other pair of side chains in ICL2 shows this property
(Fig. 5d). His-216 shows virtually no change in position; it is located
between a cavity between TMs 3, 4, and 5 and is lipid-facing (Fig. 5e).
However, it is in a very similar position to Tyr-136 of bovine rho-
dopsin, part of the DRY motif of that receptor.
DISCUSSION
Defining the precise molecular roles of residues within the intracel-
lular loops of G-protein-coupled receptors is of fundamental impor-
tance. These loops are the key to dissecting many aspects of pharmaco-
logical specificity, and individual residues within ICL2 have been shown
to distinguish between different -subunits of the G-protein complex
(9). There are few functional studies published for the analysis of the
transmembrane helix 3 proximal region of ICL2 for the family B recep-
tors, although recent observations have suggested an involvement and
possible movement of the bottom of TMs 3 and 6 in the activation of
glucagon-like peptide 1 and CL receptors (7, 31), in line with current
models of activation for the family A.
Unlike familyA, there is no crystal structure of a family BGPCR to use
for modeling studies. This is a particular problem in the region of trans-
membrane helix 3 for CLR, where two different proposals for the loop-
helix boundary have been published (10, 32). Our re-evaluation of the
likely TM-loop boundary suggests that the prediction of Chang et al.
(32) is closest to the likely structure. Having established the likely loop-
helix boundaries for ICL2, we have been able to model this region. The
data suggest that movement of ICL2 is likely to play a significant role in
CLR activation by exposing a binding pocket for G-proteins. This pre-
diction is consistent with our findings from the mutagenesis which
demonstrate that residues in the loop are implicated in activation of
adenylyl cyclase.
Alanine-scanningmutagenesis of the entire second intracellular loop
of CLR highlighted four residues or sets of residues that are important
for signaling via cAMP. (V223A/F224A)CLR and (W232A)CLR showed
small effects on surface expression and signaling. A previous study on
the prostaglandin receptors suggested that a cluster of hydrophobic
aromatic amino acids in ICL2 played a role in Gs coupling (33), and it is
possible that a similar factor is at work here. (K227A)CLR had a direct
negative effect on cAMP signaling without disrupting surface expres-
sion. The wild-type agonist affinities of all these mutants imply that,
although the residues are important for G-protein interaction (either
directly or indirectly), they are not important in stabilizing the active
conformation of the receptor around the CGRP binding state. The
native uncoupled, ground state of the receptor has a significantly lower
affinity for CGRP than the active form (7). The role for Lys-227 may
involve downstream interaction with the Gs, although it may also be a
candidate for receptor component protein interaction, which is thought
to involve an ionic combination centered around the second intracellu-
lar loop of CLR (13). An effect specific for CL is consistent with the
observation that interactions between the second intracellular loop and
the Gs subunit have been specifically dismissed for other members of
both family B (9) and family AGPCRs (34). A lysine in a similar position
in the family B parathyroid hormone receptor was shown to be required
for signal transduction (albeit Gq- and not Gs-coupled) (9). The model-
ing suggests a mechanism for the effects of Lys-227, with the side chain
pointed into a newly created cavity. It would nowbe able to interactwith
any G-protein that occupied the pocket. Interestingly, visual inspection
of the active and inactive conformations of ICL2 reveal that Lys-227 is
the only residue to be orientated closer to the G-protein binding pocket
in the active state than in the inactive state (Fig. 5c). Furthermore, the
side-chain length and charged state of Lys may make it able to form
directive interactions at longer distances, as compared with other
charged residues located in the ICL2. The modeling also sheds light on
the roles of Val-233 and Phe-234. The unique preservation of the orien-
tation of their side chains suggest that these residues may helpmaintain
the loop integrity in this region of the receptor.
A surprising result was the identification of His-216 as important for
cell-surface expression. The receptor can bind CGRP normally in cell
homogenates, suggesting that the receptor folds correctly and associ-
ates with RAMPs but fails to be translocated to the cell surface. Itmay be
part of a transport motif, or alternatively, it may act to mask an endo-
plasmic reticulum retention signal. The extreme C terminus of RAMP1
acts as an endoplasmic reticulum retention signal that must be overrid-
den after association with CLR (35); His-216 may be involved in this
process. The corresponding tyrosine to Tyr-214 in the glucagon-like
peptide 1 receptor has been proposed to be theDRY-equivalent tyrosine
residue in family B GPCRs (7, 31). Conversely, our data show that Tyr-
214 has no functionally important role in theCGRP receptor, and there-
fore, this is not part of a family B motif conserved across the entire
family. It is not out of the question that His-216, with a role in surface
expression,may be the thirdmember of a DRY equivalent. Histidine has
been shown to be a natural replacement for the tyrosine residue of the
DR(Y/H) motif of the family A V2 vasopressin receptor (36). Interest-
ingly, the V2 receptor, like the CGRP receptor, signals predominantly
through the Gs subunit. Furthermore, this third member of the family
A DR(Y/H) motif has been proposed in the m1 muscarinic receptor to
form intramolecular contacts whose integrity is required for efficient
receptor folding but does not necessarily participate directly in signaling
(37). The similarity with the effects seen for His-216 in this study is
striking. Furthermore, our modeling suggests that His-216 occupies
a similar spatial position to Tyr-136 of the DRY motif in bovine
rhodopsin.
In conclusion, this study shows that ICL2 of CLR plays an important
part in coupling the receptor to cAMP production. Modeling suggests
that the loop undergoes a significant change in conformation upon
receptor activation. Lys-227 may directly interact with Gs. However,
His-216 plays a separate role in ensuring cell-surface expression of the
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receptor. It will be interesting to discover if ICL2 plays similar roles in
other family B GPCRs.
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